NHS England bought uncertainty with managed cancer-drug access

On 29 July 2016, England changed the Cancer Drugs Fund from a rescue pot into a managed-access mechanism. Instead of a binary yes-or-no at launch, promising cancer drugs could enter under a time-limited evidence plan.

The mechanism paired clinical access with commercial discipline. NHS England and NICE negotiated with companies, used an expenditure-control mechanism to keep the fund open, and collected additional trial or real-world data during the managed access period.

By December 2024, NHS England reported about 104,267 registered patients, 117 drugs and 284 cancer indications under the new approach. It said 60 managed access agreements had been made and 34 of 39 reappraised treatments were later recommended for routine commissioning.

Fund the option, then buy the evidence

Patients did not have to wait for all uncertainty to disappear before accessing promising drugs.

NICE kept the final funding decision tied to evidence rather than launch pressure.

Companies accepted discounts and data obligations in exchange for earlier NHS access.

The fixed budget and expenditure controls prevented open-ended commitments.

For uncertain innovations, the buyer can separate access from final adoption: pay temporarily, collect the missing evidence and reserve the right to stop.

The model became a template for wider managed access in England, including the Innovative Medicines Fund. NHS England's 2024-25 update said the CDF had a GBP 340 million annual budget and was operating within its funding envelope at the end of Q2.